Qscreen Ai Inc. (PMEDF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Qscreen Ai Inc. (PMEDF) with AI Score 44/100 (Weak). QScreen AI, Inc. is a life sciences technology company focused on developing AI-powered technologies for workplace health and safety, and healthcare applications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Qscreen Ai Inc. (PMEDF) Healthcare & Pipeline Overview
QScreen AI, Inc. develops AI-powered technologies for workplace health and safety and the healthcare industry, providing tools for medical professionals. The company, founded in 1987 and headquartered in Toronto, operates in the competitive medical devices sector, facing challenges typical of early-stage technology ventures.
Investment Thesis
QScreen AI, Inc. presents a high-risk, high-reward investment opportunity, contingent on the successful development and commercialization of its AI-powered healthcare technologies. With a market capitalization of $0.01 billion and a negative P/E ratio of -9.06, the company is currently not profitable, reflecting its early stage of development. Key value drivers include the successful application of AI in healthcare settings, leading to increased efficiency and improved patient outcomes. Growth catalysts include potential partnerships with healthcare providers and the expansion of its product offerings. However, potential risks include intense competition, the need for significant capital investment, and regulatory hurdles in the healthcare industry. The company's high beta of 1.45 indicates significant volatility, making it suitable only for investors with a high-risk tolerance.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -9.06 reflects the company's current lack of profitability, typical for early-stage technology companies.
- Beta of 1.45 suggests higher volatility compared to the market, indicating a riskier investment.
- Focus on AI-powered technologies positions the company in a high-growth area within the healthcare sector.
- Headquartered in Toronto, Canada, providing access to a strong talent pool and a supportive ecosystem for technology companies.
Competitors & Peers
Strengths
- Focus on AI, a high-growth area in healthcare.
- Potential to improve efficiency and accuracy in medical settings.
- Innovative approach to workplace health and safety.
- Experienced leadership team.
Weaknesses
- Small market capitalization.
- Currently not profitable.
- Limited market presence.
- Dependence on successful development and commercialization of AI technologies.
Catalysts
- Upcoming: Potential partnerships with healthcare providers could drive adoption of QScreen AI's technologies.
- Ongoing: Development and launch of new AI-powered diagnostic tools could expand the company's product offerings.
- Ongoing: Geographic expansion into new markets could increase revenue and market reach.
Risks
- Potential: Intense competition from established medical device manufacturers could limit market share.
- Potential: Regulatory hurdles in the healthcare industry could delay or prevent the commercialization of its AI solutions.
- Ongoing: The need for significant capital investment could strain the company's financial resources.
- Potential: Rapid technological advancements could render its AI solutions obsolete.
- Ongoing: Limited financial disclosure due to OTC Other tier status.
Growth Opportunities
- Expansion into new therapeutic areas represents a significant growth opportunity for QScreen AI. By leveraging its AI platform to address unmet needs in specific medical specialties, such as cardiology, oncology, or neurology, the company can diversify its revenue streams and reduce its reliance on a single product or market. The market size for AI in each of these therapeutic areas is substantial, potentially reaching billions of dollars within the next 3-5 years.
- Strategic partnerships with healthcare providers and hospitals can accelerate the adoption of QScreen AI's technologies. By collaborating with key stakeholders in the healthcare ecosystem, the company can gain access to valuable data, clinical expertise, and distribution channels. These partnerships can also help validate the effectiveness of its AI solutions and build trust among potential customers. The timeline for establishing these partnerships is ongoing, with potential deals expected to materialize within the next 12-24 months.
- Geographic expansion into new markets, particularly in North America and Europe, offers significant growth potential. By targeting countries with well-developed healthcare systems and a high adoption rate of new technologies, QScreen AI can increase its market reach and revenue. This expansion will require careful planning and execution, including regulatory approvals, market research, and the establishment of local sales and support teams. The timeline for geographic expansion is estimated at 2-3 years.
- Development of new AI-powered diagnostic tools represents a key growth opportunity. By leveraging its expertise in artificial intelligence, QScreen AI can create innovative solutions that improve the accuracy and speed of diagnosis, leading to better patient outcomes. The market for AI-powered diagnostic tools is rapidly expanding, driven by the increasing availability of medical data and the growing demand for personalized medicine. The timeline for developing and launching these new tools is estimated at 2-3 years.
- Integration of AI into workplace health and safety programs presents a unique growth opportunity. By offering AI-powered solutions that monitor employee health and safety, QScreen AI can help companies reduce workplace accidents, improve productivity, and lower healthcare costs. The market for workplace health and safety solutions is substantial, with increasing demand for technologies that promote employee well-being. The timeline for penetrating this market is estimated at 1-2 years.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships with healthcare providers.
- Geographic expansion into new markets.
- Development of new AI-powered diagnostic tools.
Threats
- Intense competition from established medical device manufacturers.
- Regulatory hurdles in the healthcare industry.
- Need for significant capital investment.
- Rapid technological advancements that could render its AI solutions obsolete.
Competitive Advantages
- Proprietary AI algorithms and technologies.
- Expertise in applying AI to healthcare and workplace safety.
- Potential for network effects as more users adopt its AI solutions.
- Data assets generated from AI applications.
About PMEDF
QScreen AI, Inc., established on September 3, 1987, and based in Toronto, Canada, is a life sciences technology company specializing in the development of artificial intelligence (AI) powered technologies. These technologies are designed for application in both general workplace health and safety and within the broader healthcare industry. The company focuses on providing tools intended for use by medical professionals, aiming to enhance their capabilities through AI-driven solutions. QScreen AI's business model centers around creating and deploying AI technologies that can address specific needs within the healthcare sector. While specific products and services are not detailed, the company's focus on AI suggests a portfolio that may include diagnostic tools, monitoring systems, or platforms designed to improve efficiency and accuracy in medical settings. The company's success will depend on its ability to innovate and effectively market its AI solutions to healthcare providers and organizations. The company operates within the competitive medical devices industry, facing established players and emerging technology firms. QScreen AI's ability to differentiate itself through unique AI applications and strategic partnerships will be critical for its long-term growth and sustainability. The company's early stage and small market capitalization also present challenges related to funding, market penetration, and scaling operations.
What They Do
- Develops AI-powered technologies for workplace health and safety.
- Creates AI solutions for the healthcare industry.
- Provides tools for medical professionals.
- Focuses on improving efficiency and accuracy in medical settings through AI.
- Aims to enhance diagnostic capabilities using AI.
- Works to improve patient outcomes through AI-driven solutions.
Business Model
- Develops and licenses AI-powered technologies to healthcare providers.
- Generates revenue through software licensing fees.
- May offer subscription-based access to its AI platforms.
- Potentially generates revenue through data analytics services.
Industry Context
QScreen AI, Inc. operates within the medical devices industry, a segment experiencing rapid growth due to technological advancements and increasing demand for innovative healthcare solutions. The integration of artificial intelligence (AI) into medical devices is a significant trend, offering the potential to improve diagnostics, treatment, and patient care. The competitive landscape includes established medical device manufacturers and emerging AI-focused companies. QScreen AI's success depends on its ability to differentiate itself through unique AI applications and strategic partnerships. The global medical device market is projected to reach hundreds of billions of dollars in the coming years, presenting substantial opportunities for growth.
Key Customers
- Hospitals and healthcare systems.
- Medical professionals, including doctors and nurses.
- Workplace health and safety managers.
- Corporations seeking to improve employee health and safety.
Financials
Chart & Info
Qscreen Ai Inc. (PMEDF) stock price: Price data unavailable
Latest News
No recent news available for PMEDF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PMEDF.
Price Targets
Wall Street price target analysis for PMEDF.
MoonshotScore
What does this score mean?
The MoonshotScore rates PMEDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sheldon Kales
CEO
Sheldon Kales is the CEO of QScreen AI Inc. His background and experience are not detailed in the provided information. Further research would be needed to provide a comprehensive profile, including his career history, education, and previous roles. Without this information, it is difficult to assess his specific qualifications for leading QScreen AI.
Track Record: Due to the lack of available information regarding Sheldon Kales's background and experience, it is not possible to assess his track record or identify key achievements, strategic decisions, or company milestones under his leadership. Further research is required to evaluate his performance as CEO of QScreen AI.
PMEDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that QScreen AI may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies often have very limited operating history or assets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Low liquidity and high bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher volatility compared to exchange-listed stocks.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's cash flow and financial stability.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues involving the company.
- Company is registered in Canada and has a physical headquarters in Toronto.
- Focus on AI technology, a potentially high-growth area.
- Company has been in existence since 1987.
- Development of technologies for workplace health and safety, and healthcare industry
Common Questions About PMEDF
What does Qscreen Ai Inc. do?
QScreen AI, Inc. is a life sciences technology company specializing in the development of AI-powered technologies for workplace health and safety, and for the healthcare industry. The company focuses on providing tools for medical professionals, aiming to improve efficiency, accuracy, and patient outcomes through AI-driven solutions. While specific products and services are not detailed, the company's focus on AI suggests a portfolio that may include diagnostic tools, monitoring systems, or platforms designed to improve healthcare processes.
What do analysts say about PMEDF stock?
There is currently no available analyst coverage or consensus on PMEDF stock. The company's small market capitalization of $0.01 billion and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before considering an investment in PMEDF, considering the risks associated with OTC stocks and the company's early stage of development. Key valuation metrics, such as revenue growth and profitability, are not available, making it difficult to assess the company's financial performance.
What are the main risks for PMEDF?
The main risks for QScreen AI, Inc. include intense competition from established medical device manufacturers, regulatory hurdles in the healthcare industry, the need for significant capital investment, and the potential for rapid technological advancements to render its AI solutions obsolete. Additionally, as an OTC-listed company, PMEDF faces risks related to limited financial disclosure, low liquidity, potential price manipulation, and higher volatility compared to exchange-listed stocks. Investors should carefully consider these risks before investing in PMEDF.
What are the key factors to evaluate for PMEDF?
Qscreen Ai Inc. (PMEDF) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on AI, a high-growth area in healthcare.. Primary risk to monitor: Potential: Intense competition from established medical device manufacturers could limit market share.. This is not financial advice.
How frequently does PMEDF data refresh on this page?
PMEDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PMEDF's recent stock price performance?
Recent price movement in Qscreen Ai Inc. (PMEDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on AI, a high-growth area in healthcare.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PMEDF overvalued or undervalued right now?
Determining whether Qscreen Ai Inc. (PMEDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PMEDF?
Before investing in Qscreen Ai Inc. (PMEDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to the provided sources.
- Lack of financial data and analyst coverage limits the depth of the analysis.
- OTC stocks carry significant risks that investors should be aware of.